cat no | io1001
ioGlutamatergic Neurons have been precision reprogrammed from human induced pluripotent stem cells (iPSC) using opti-ox™ technology. Within days, cells convert consistently to mature, functional glutamatergic neurons characterised by >80% expression of glutamate transporter genes VGLUT1 and VGLUT2.
Glutamatergic neurons are delivered cryopreserved and ready-to-culture making them a high-quality human model for fundamental research, disease modelling and drug discovery.
per vial
A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@bit.bio.
Click here for bulk request
Quick
Ready for experimentation as early as 2 days post revival and form functional neuronal networks at 17 days.
Scalable
Industrial scale quantities at a price point that allows the cells to be used from research to screening scale.
Easy to use
Cells arrive programmed to rapidly mature upon revival. One medium is required in a two-step protocol.
ioGlutamatergic Neurons generated by transcription factor-driven reprogramming of iPSCs using opti-ox technology
Time-lapse video capturing the rapid and homogeneous neuronal phenotype acquisition upon thawing of cryopreserved ioGlutamatergic Neurons. 7 day time course.
ioGlutamatergic Neurons express glutamatergic neuron-specific markers
Immunofluorescent staining on post-revival day 11 demonstrates homogenous expression of the pan-neuronal protein, MAP2 and glutamatergic neuron-specific transporter, VGLUT2.
ioGlutamatergic Neurons form structural neuronal networks by day 11
ioGlutamatergic Neurons mature rapidly and form structural neuronal networks over 11 days. Day 1 to 11 post thawing; 100X magnification.
Examples of MaxOne high-resolution multi electrode array (MEA) recordings of ioGlutamatergic Neurons in BrainPhys™ media. The activity maps show firing rate (A), spike amplitude (B) and % of active electrodes (C). Results demonstrate a time-dependent increase of spontaneous activity during neuronal maturation from 2 to 3 weeks post-revival.
Iovino, M. et al., 2019, Charles River Laboratories.
Cells demonstrate a time-dependent increase of spontaneous bursting activity over a three-week period
Click on the tabs to explore the data.
(A) The graph shows the % of active bursting electrodes for each time point. (B) An example of a spontaneous spike, taken at day 8 post-revival (1 second sweep, 32 µV/-18 µV). (C) An example of a bursting phenotype, taken at day 20 post-revival (1 second sweep, 16 µV/-16 µV). Cells were cultured in the bit.bio recommended open-source medium and recorded on 64-electrode MEAs.
NDimension (Science and Engineering) Ltd.
ioGlutamatergic Neurons co-cultured with rat-derived astrocytes demonstrate time-dependent increase in synchronous activity
Click on the tabs to explore the data.
Array Wide Spike Detection Rate histograms (AWSDR – a graphical measure of synchrony) for 10-minute recordings on day 8, 13 and 20 post-revival ioGlutamatergic Neurons in co-culture with primary rat-derived astrocytes. Results show prominent synchronicity on day 13, exemplified by the ‘spikier’ nature of the associated AWSDR, which increases at day 20. Cells were cultured in the bit.bio recommended open-source medium and recorded on 64-electrode MEAs.
NDimension (Science and Engineering) Ltd.
ioGlutamatergic Neurons show good suitability for high-throughput screening in 384-well format plates
Cytotoxicity CellTiter-Glo®️ (CTG) and TR-FRET (HTRF®️) assays for AKT serine/threonine kinase 1 (AKT) and Huntingtin (HTT) proteins were performed on ioGlutamatergic Neurons in 384-well plates treated with tool compound (cmp) at day 9 post-revival. Compound titration results in a concentration response curve for all three assays (mean±sd of 2 replicates). CTG assay on ioGlutamatergic Neurons shows an excellent average signal/ background ratio and high suitability for HTS. HTRF® assays on ioGlutamatergic Neurons show lower signals but with low variability, and could therefore also provide a suitable platform for HTS.
Iovino, M. et al., 2019, Charles River Laboratories.
Do more with every vial
The seeding density of our human iPSC-derived glutamatergic neurons has been optimised and validated making it possible to have a cost point of under £0.67 (~$0.79) per well (96 well plate, seeding density 30,000 cells/cm2, Large vial size).
This means scientists are able to do more with every vial and expand experimental design within budget without losing out on quality. Resulting in more experimental conditions, more repeats, and more confidence in the data.
One Small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plate.
One Large vial can plate a minimum of 3.6 x 24-well plate, 5.4 x 96-well plate, or 7.75 x 384-well plates.
Cells arrive ready to plate
ioGlutamatergic Neurons are delivered in a cryopreserved format and are programmed to rapidly mature upon revival in the recommended media. The protocol for the generation of these cells is a three-phase process: 1. Induction (carried out at bit.bio) 2. Stabilisation for 4 days 3. Maintenance during which the neurons mature.
Starting material
Human iPSC line
Karyotype
Normal (46, XY)
Seeding compatibility
6, 12, 24, 48, 96 & 384 well plates
Shipping info
Dry ice
Donor
Caucasian adult male (skin fibroblast)
Vial size
Small: >1 x 10⁶ viable cells Large: >5 x 10⁶ viable cells
Quality control
Sterility, protein expression (ICC) and gene expression (RT-qPCR)
Differentiation method
opti-ox cellular reprogramming
Recommended seeding density
30,000 cells/cm²
User storage
LN2 or -150°C
Format
Cryopreserved cells
Product use
ioCells are for research use only
Applications
Drug discovery
Neurotoxicology
High throughput screening
CRISPR Screening
3D bioprinting
Emmanouil Metzakopian | Vice President, Research and Development | bit.bio
Javier Conde-Vancells | Director Product Management | bit.bio
Whitehouse et al.
JoVE Journal of Visualized Experiments
2023
Using ioGlutamatergic Neurons
Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | bit.bio
Innovation showcase talk at ISSCR
Marius Wernig MD, PhD | Stanford
Mark Kotter, MD, PhD | bit.bio
Dr Tony Oosterveen, et al.
bit.bio & Charles River Laboratories
2023
V7
bit.bio
2023
Mark Kotter | CEO and founder | bit.bio
Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology | Stanford University
Madeleine Garrett | Field Application Specialist | bit.bio
Read this blog to find out how our precision cellular reprogramming technology, opti-ox is powering cell identity, giving you easy access to endless and reliable human cells!
Be confident in your data by pairing ioDisease Model cells with the genetically matched ioWild Type control